

1 **Clinical characteristics of pregnant women infected with Coronavirus Disease**
2 **2019 in China: a nationwide case-control study**

3 Qin Li^{*}, Lian Chen^{*}, Hai Jiang^{*}, Danni Zheng^{*}, Yuanyuan Wang, Jie Mei, Xudong
4 Ma[†], Yuan Wei[†], Yangyu Zhao[†], Jie Qiao[†]

5
6 * These authors contributed equally and are considered co-first authors

7 † These authors contributed equally and are considered co-corresponding authors

8
9 **National Clinical Research Center for Obstetrical and Gynecology, National**
10 **Center for Healthcare Quality Management in Obstetrics, Ministry of Education**
11 **Key Laboratory of Assisted Reproduction, Department of Obstetrics and**
12 **Gynecology, Peking University Third Hospital, Beijing, China** (Prof. Jie Qiao, MD
13 & PhD, Prof. Yangyu Zhao, MD & PhD, Yuan Wei MD & PhD, Qin Li PhD, Lian
14 Chen MD & PhD, Hai Jiang PhD, Danni Zheng PhD, Yuanyuan Wang PhD);

15
16 **Department of Obstetrics and Gynecology, Sichuan Province**
17 **People's Hospital, Chengdu, China** (Jie Mei, MD)

18
19 **National Health Commission of the People's Republic China, Beijing, China**
20 (Xudong Ma, M.Med)

21
22 **Correspondence to:**

23 National Center for Healthcare Quality Management in Obstetrics, National Clinical
24 Research Center for Obstetrical and Gynecology, Ministry of Education Key
25 Laboratory of Assisted Reproduction, Department of Obstetrics and Gynecology,
26 Peking University Third Hospital, Beijing 100191, China. **jie.qiao@263.net**

27

28 **ABSTRACT**

29 **OBJECTIVE**

30 To formally compare the clinical course of Coronavirus disease 2019 (COVID-19) in
31 pregnant women with their nonpregnant counterparts.

32

33 **METHODS**

34 Clinical data of pregnant women with confirmed COVID-19 in the designated
35 hospitals of mainland China were retrieved up to April 12, 2020 through an epidemic
36 reporting system maintained at the National Health Commission of the People's
37 Republic China. Each pregnant patient was randomly matched to a nonpregnant
38 woman with confirmed COVID-19 in the same hospital as control, then their clinical
39 courses were formally compared.

40

41 **RESULTS**

42 138 pregnant women had been identified as confirmed COVID-19 cases. Among them,
43 17 severe cases and 1 maternal death were recorded, which was less than their
44 nonpregnant peers (23 severe cases and 3 death). 57.2% had been infected with
45 SARS-CoV-2 during the third trimester, including 13 severe cases and 1 maternal
46 death. 7.3% of pregnant patients had diarrhea and 3.6% had nausea or vomiting,
47 compared with related proportion as 15.2% (OR: 0.38, 95%CI: 0.15, 0.96) and 10.1%
48 (OR: 0.25, 95%CI: 0.07, 0.89) in nonpregnant patients. Pregnant patients infected
49 with SARS-CoV-2 in early pregnancy presented similar laboratory tests with their
50 nonpregnant peers, however, with pregnancy progresses, increased inflammation,
51 coagulation and hepatic injury markers happened more and more frequently ($p<0.001$)
52 in pregnant patients.

53

54 **CONCLUSIONS**

55 Being pregnant did not represent a risk for severe condition when compared with their
56 nonpregnant peers. Patients infected with SARS-CoV-2 in early pregnancy were even

57 at lower risk of severe illness than those infected in late pregnancy.

58

59 **Key word:** COVID-19, SARS-CoV-2, pregnancy, case-control study

60

61 **What are the novel findings of this work?**

62 Compared with non-pregnant COVID-19 patients, pregnant patients tend to present
63 less symptom, had unique laboratory findings, and tend to at lower risk of
64 COVID-19–related death. Patients infected with SARS-CoV-2 in the early pregnancy
65 tend to be in the less severe condition of illness than those infected in late pregnancy.

66

67 **What are the clinical implications of this work?**

68 Vital comparisons of the clinical course upon COVID-19 between pregnant and
69 nonpregnant women in childbearing age are, unfortunately, lacking. Through formally
70 comparisons between the two groups, the present study provides more reliable
71 evidence towards the management of pregnant women with COVID-19.

72 **Introduction**

73 Due to the high infectivity of severe acute respiratory syndrome coronavirus 2
74 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) caused by the virus has spread
75 quickly in worldwide, and was declared by the World Health Organization (WHO) as
76 a Public Health Emergency of International Concern (PHEIC). Over the past six
77 months, more than 10 million confirmed cases of COVID-19 had been documented
78 globally, resulting in more than 500,000 deaths.¹

79

80 According to the previous studies which were relevant to severe acute respiratory
81 syndrome (SARS) and middle east respiratory syndrome (MERS), pregnant women
82 were more susceptible to coronavirus infection, and they were also at a high risk of
83 poor outcomes, including need for mechanical ventilation, admission to an intensive
84 care unit (ICU), renal failure and death.² Considering that SARS-CoV-2 has up to 80%
85 sequence similarity with SARS-CoV,³ a number of literatures suggested that pregnant
86 women might be at higher risk to develop a more severe form of COVID-19 results
87 from the physiological immunosuppression.⁴ More worrying, according to a recently
88 report of the Centre for Disease Control and Prevention of United States (U.S. CDC),
89 8,207 pregnant women had laboratory-confirmed SARS-CoV-2 infections were
90 documented in America up to June 16, 2020, and the number kept sustainable
91 growing.⁵ Thus, the impact of COVID-19 on pregnant women has drawn great public
92 attention.

93

94 Studies include ours tried to describe the clinical features of pregnant COVID-19
95 patients,^{6,7} while the interaction between SARS-CoV-2 infection and physiological
96 change during pregnancy is not already clear. Vital comparisons of the clinical course
97 upon COVID-19 between pregnant and nonpregnant women in childbearing age are,
98 unfortunately, lacking. It is therefore an emerging need to figure out the questions
99 including whether pregnant women with COVID-19 present distinct manifestations as

100 well as laboratory tests to their nonpregnant peers, whether pregnant women infected
101 with SARS-CoV-2 in different gestation had similar presentation and whether being
102 pregnant represents a risk for severity clinical presentation.

103

104 Based on an epidemic reporting system maintained at the National Health
105 Commission of the People's Republic China (NHCPRC), we conducted a 1:1
106 case-control study to formally compare the clinical course of COVID-19 in pregnant
107 women with their nonpregnant peers. With the significant results, we are aiming to
108 provide a update insight into the management for pregnant population during the
109 COVID-19 pandemic.

110

111 **Methods**

112 *Study design*

113 Patients with COVID-19 in mainland China were admitted in designated hospitals
114 during the outbreak. All designated hospitals were invited to upload the medical
115 records of COVID-19 patients through an epidemic reporting system maintained at
116 NHCPRC. Under the coordination of NHCPRC, we conducted a 1:1 matched
117 case-control study based on the epidemic reporting system. The study was approved
118 in accordance with the agreed procedure with the Ethics Committee of Peking
119 University Third Hospital, waiving written informed consent for deidentified patient
120 data.

121

122 *Selection of cases and controls*

123 The aim of the present study was to estimate the impact of pregnant status on the
124 progression of COVID-19. Thus, 'cases' were defined as pregnant COVID-19 patients.
125 According to the criterion of Chinese Clinical Guidance for COVID-19 Pneumonia
126 Diagnosis and Treatment (Seventh Edition, released by the NHCPRC), we collected
127 all 138 pregnant women who were confirmed cases of COVID-19 through the

128 epidemic reporting system, including all the 84 laboratory-confirmed cases in Wuhan
129 city which was mentioned in our previous report.⁶ Each pregnant patient was matched
130 to a confirmed patient who was non pregnant, with same age and admitted in same
131 hospital as ‘control’ by simple randomization. 11 cases cannot be matched within the
132 same hospital due to the rare number of COVID-19 patients there, then adequate
133 controls were compensated from other hospitals within the same city. All uploaded
134 medical records of them were retrieved from the epidemic reporting system, then we
135 extracted information regarding epidemiological, clinical, laboratory and radiological
136 characteristics, treatment, and outcomes of them with a customized data collection
137 form. All data collection forms were reviewed by two experienced doctors
138 independently to insure data reliability. Major disagreement between them was
139 resolved by consultation to a third doctor. The data cutoff for the study was from
140 December 8, 2019 to April 12, 2020.

141

142 *Study definitions*

143 A confirmed case of COVID-19 was defined as a suspected case with positive result
144 for SARS-CoV-2 on high throughput sequencing or real-time reverse transcriptase
145 polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swab specimens.
146 The degree of severity (severe and critical case) was classified by using the mentioned
147 guidance. Severe cases were defined as meeting one of these conditions: 1)
148 respiratory rate ≥ 30 breaths/min; 2) arterial oxygen tension (PaO₂) over inspiratory
149 oxygen fraction (FIO₂) of less than 300 mmHg; 3) Percutaneous oxygen saturation
150 (SpO₂) $\leq 93\%$ on room air at rest. Critical cases were defined as on the following
151 conditions: 1) occurrence of severe respiratory distress; 2) respiratory failure requiring
152 mechanical ventilation; 3) shock and organ failure even needs of ICU care.

153

154 *Statistical analysis*

155 Continuous variables were expressed as medians and interquartile ranges (IQR).

156 Categorical variables were expressed as counts and percentages (%). No imputation
157 was made for missing data. Pairs chi-square test and odds ratios with corresponding
158 95% confidence interval was used to justify the difference between pregnant patients
159 and nonpregnant patients for categorical features.⁸ Paired t-test was used to justify the
160 difference between pregnant patients and nonpregnant patients for continuous
161 features. We used $p < 0.05$ (2-tailed) to determine statistical significance. All statistics
162 analyses were done with R software (R core team, version 3.4.0).

163

164 **Results**

165 We identified a total of 138 pregnant COVID-19 patients across mainland China. The
166 largest number of pregnant patients (102) came from Hubei province, followed by the
167 provinces bordering Hubei (Figure 1). Baselines of the pregnant patients and their
168 nonpregnant peers are shown in Table 1. The median age of the pregnant patients was
169 30.4 years (standard deviation: 4.3). 79 of 138 (57.2%) had been infected with
170 SARS-CoV-2 in the third trimester. A total of 121 pregnant patients (87.7%) had mild
171 disease, while 17 pregnant patients (12.3%) had severe disease (hypoxemia). 8
172 pregnant patients (5.8%) had complications (hypertension, diabetes, choric hepatitis,
173 or choric nephritis). 1 maternal death was observed in the electronic medical records.
174 For their nonpregnant peers, 23 patients (16.7%) had severe disease, 17 patients
175 (12.3%) had complications (hypertension, diabetes, choric hepatitis, or choric
176 nephritis), and 3 death were recorded.

177

178 Table 2 presents the clinical features of pregnant COVID-19 patients by gestation. For
179 manifestations, dyspnea was presented in 15% of the pregnant patients infected with
180 SARS-CoV-2 in the third trimester and presented in 7% of the pregnant patients
181 infected in early pregnancy. For laboratory tests, compared with patients infected with
182 SARS-CoV-2 in early pregnancy, pregnant patient infected in late pregnancy were
183 more likely to present reduced lymphocytes, hemoglobin, and albumin levels ($p < 0.05$),

184 as well as elevated fibrinogen, D-dimer, lactate dehydrogenase (LDH), creatine kinase
185 (CK), C-reactive protein (CRP) and procalcitonin (PCT) levels ($p<0.05$). For
186 treatment, a higher proportion of pregnant patients infected in late pregnancy needed
187 oxygen support ($p<0.05$) and invasive mechanical ventilation. Overall, we also
188 noticed that 13 of the 17 severe cases were infected in the third trimester (one of them
189 had died), and the other 4 severe cases were infected in the second trimester.

190

191 Clinical features of the pregnant COVID-19 patients were compared with their
192 nonpregnant peers in Table 3. Pregnant patients tend to present less symptom than
193 nonpregnant patients during hospitalization. Among the pregnant patients, 16.1% had
194 fatigue, 7.3% had diarrhea and 3.6% nausea or vomiting, however, for their
195 nonpregnant peers, 30.4% had fatigue (OR: 0.44, 95%CI: 0.25, 0.80), 15.2% had
196 diarrhea (OR: 0.38, 95%CI: 0.15, 0.96) and 10.1% had nausea or vomiting (OR: 0.25,
197 95%CI: 0.07, 0.89). On the other hand, 8.0% of the pregnant patients had no signs or
198 symptoms of the disease, while the proportion was 4.3% among their nonpregnant
199 peers, with a OR of 1.83 (95%CI: 0.68, 4.96).

200

201 On admission, the median value of leukocyte counts was $6.5\times 10^9/L$ among pregnant
202 patients, which was higher than that of nonpregnant patients ($4.7\times 10^9/L$, $p<0.001$). 5.2%
203 of the pregnant patients had leukopenia, while 18.5% of the nonpregnant patients had
204 leukopenia, with a OR of 0.26 (95%CI: 0.11, 0.64). The median value of lymphocytes
205 was $1.1\times 10^9/L$ among pregnant patients, which was lower than that of their
206 nonpregnant peers ($1.4\times 10^9/L$, $p<0.001$). 50.8% of the pregnant patients had
207 lymphopenia, while only 30.8% of the nonpregnant patients had lymphopenia, with a
208 OR of 2.04 (95%CI: 1.24, 3.36). When we focus on the women infected in early
209 pregnancy and their nonpregnant peers, the distinctions on leukocytes and
210 lymphocytes disappeared (Table S1, S2 and S3 in appendix). We also found pregnant
211 patients had a lower level of hemoglobin and albumin than their nonpregnant peers

212 ($p<0.001$), but they had a higher level of fibrinogen, D-dimer, alanine
213 aminotransferase (ALT), aspartate aminotransferase (AST), LDH and CRP than their
214 nonpregnant peers ($p<0.05$). Similarly, there was no longer a significant difference on
215 those biomarkers when we focus on the women infected in early pregnancy and their
216 nonpregnant peers (Table S1, S2 and S3 in appendix).

217

218 For radiographic findings, 118 of the pregnant patients and 131 of the nonpregnant
219 patients had performed CT scans. 76.3% of the pregnant patients showed bilateral
220 involvement on the chest CT, which was higher than that of their nonpregnant peers
221 (61.1%), with a OR of 2.38 (95%CI: 1.25, 4.56). For treatment, 73.9% of the pregnant
222 patients were given antiviral therapy, which was lower than the proportion of their
223 nonpregnant peers, with a OR of 0.09 (95%CI: 0.03, 0.30). Similarly, the proportion
224 of pregnant patients who received traditional Chinese medicine treatment was 42.0%,
225 which was lower than that of nonpregnant patients, with a OR of 0.36 (95%CI: 0.21,
226 0.62).

227

228 **Discussion**

229 Through the epidemic reporting system maintained at the NHCPRC, we recruited a
230 total of 138 pregnant women confirmed with COVID-19 across mainland China. By
231 analyzing their clinical characteristics, we found pregnant women tend to present less
232 symptom, had unique laboratory findings, and tend to at lower risk of
233 COVID-19–related death. Additionally, we also found patients infected with
234 SARS-CoV-2 in the early pregnancy tend to be in the less severe condition of illness
235 than those infected in late pregnancy. To our best knowledge, this is the first study
236 provide detailed information regarding SARS-CoV-2 infection in different gestation
237 as well as a formally comparison of the clinical course of COVID-19 between
238 pregnant women and nonpregnant women. These findings are essential for
239 understanding of COVID-19 and improving clinical guidance for management of

240 pregnant COVID-19 patients.

241

242 In our study, we found the overall incidence of clinical symptoms during
243 hospitalization is lower than that of nonpregnant women, which is consistent with the
244 largest epidemic report of 3,474 pregnant COVID-19 patient from U.S. CDC⁵, as they
245 also indicated that pregnant women less frequently reported headache, muscle aches,
246 fever, chills, and diarrhea than did nonpregnant women. We further noted that the
247 incidence of gastrointestinal symptoms was significantly lower in pregnant women
248 than nonpregnant women, and it was also lower than that of the report of the U.S.
249 CDC (3.6% versus 19.6% had nausea or vomiting; 7.3% versus 14.3% had diarrhea).⁵
250 The widely use of antiviral drugs may affect the incidence of gastrointestinal
251 symptoms such as nausea and vomiting, thus we had defined symptoms as the
252 incidence at admission to exclude the influence of this factor in the analysis, which
253 may contribute to the difference. Digestive symptoms imply that viral load and
254 replication within the gastrointestinal tract, which was associated with more severe
255 illness as studies had shown that COVID-19 patients without digestive symptoms are
256 more likely to be cured and discharged than patients with digestive symptoms.⁹ These
257 findings suggested that signs and symptoms of COVID-19 might differ between
258 pregnant and nonpregnant women, which can also serve as evidence for the inference
259 that pregnant women tend to have mild illness than their nonpregnant peers.

260

261 With the physiological change during pregnancy, many laboratory indicators altered
262 gradually. Comparing to nonpregnant women, the serum albumin and hemoglobin
263 concentration decreases due to hemodilution; coagulation is augmented following
264 with an increased fibrinogen and D-dimer concentration in pregnant population.¹⁰
265 Leukocyte counts increased and lymphocytes counts decreased as gestation proceeds
266 due to the gradual increase in neutrophils counts.¹¹ When compared pregnant patients
267 with their nonpregnant peers, consistent features were observed as we found

268 leukopenia is less common while lymphopenia and elevated fibrinogen, D-dimer,
269 LDH and CRP levels are more common in pregnant patients than their nonpregnant
270 peers. However, these distinctions showed corresponding trend as pregnancy
271 physiological changes by the gestational week and were observed during the second
272 and third trimesters mainly, which also supported that these distinctions may be
273 caused by the physiological change during pregnancy mainly. Therefore, the
274 immanent physiological characteristics during pregnancy should be fully considered
275 when using laboratory test results (e.g., leukocyte and lymphocytes counts) as basis
276 for diagnosis and evaluation of illnesses among pregnant patients.

277

278 In contrast, abnormal liver function was more common among pregnant COVID-19
279 patients than that of their nonpregnant peers. The incidence of abnormal liver function
280 was up to 23% in pregnant patients, and even remained at 15% in women who had
281 been infected with SARS-CoV-2 in early pregnancy, which can hardly be explained
282 by the physiological changes of pregnancy. Preliminary studies indicated that
283 SARS-CoV-2 can attack several organs which involves not just lung but also heart
284 and liver.¹² However, with the available evidence at present, we cannot clarify
285 whether pregnancy could increase the risk of liver damage associated with
286 SARS-Cov-2 infection, but monitoring and evaluation of liver function in pregnant
287 patients should be performed and more attention should be paid.

288

289 It is well document that analogous coronaviruses such as SARS-CoV infection can
290 cause severe respiratory disease among pregnant women with a high fatality rate.¹³
291 However, in the nationwide case-control study, we found being pregnant didn't
292 represent a risk for severity of clinical presentation and maternal death in
293 SARS-Cov-2 infection, which may be related to the special pathogenic mechanism of
294 SARS-Cov-2 and the unique pregnancy immune status of pregnant women.¹⁴ In the
295 case of SARS-CoV infection, the immune response of Th1 type is highly activated

296 and lasts for a long time, resulting in a consistently high level of pro-inflammatory
297 cytokine expression, which may be responsible for extensive target organ damage.¹⁵
298 For SARS-CoV-2 infection, the intensity and duration of Th2 immune responses were
299 similar with Th1,¹³ which may mitigate pro-inflammatory cytokine expression and the
300 resulting organ damage. During pregnancy, the maternal immune system will make
301 real-time adjustments to resist the invasion of pathogens as well as to tolerate the
302 implantation of fetus and placenta.¹⁶ This specific change of immune state is believed
303 to be related to the tilt of the immune balance of Th1/Th2 to Th2. Th2 predominant
304 immune balance and the role of Treg cells may play an important role in preventing
305 excessive systemic inflammatory response such as cytokines storms and following
306 life-threatening organ failure.¹⁷ These features of SARS-CoV-2 infection and
307 pregnancy may contribute to the relatively mild illness among pregnant patients. On
308 the other hand, Little, Zheng and their colleagues suggested that viral load, defined as
309 the size of the infecting dose of SARS-CoV-2, is likely to be important for the
310 severity of disease,^{18,19} which implied that the mild condition of pregnant women may
311 also associated with their lower exposure due to strengthen self-protection measures.

312

313 Among pregnant COVID-19 patients, we noted that patients infected with
314 SARS-CoV-2 in the late pregnancy tend to be in the more severe condition of illness
315 than those infected in early pregnancy, as 13 of the all 17 severe cases in our study
316 were infected in the late pregnancy (one of them had passed away), and a higher
317 proportion of pregnant patient infected in late pregnancy presented dyspnea who
318 needed oxygen support or even invasive mechanical ventilation. Higher oxygen
319 demands due to pregnancy-associated anatomical and physiological adaptive changes
320 (e.g., diaphragm elevation, increased oxygen consumption, incremental circulation
321 volume and edema of respiratory tract mucosa) in the cardio-respiratory system,
322 increased risk of pulmonary microvascular thrombosis due to pregnancy-associated
323 hypercoagulable state could all have an important role in the clinical course of

324 SARS-CoV-2 infection during the third trimester of pregnancy.²⁰

325

326 We also noted that a certain number of maternal deaths caused by COVID-19 were
327 reported by various country and regions.^{5 21 22} According to the report of U.S. CDC,
328 there were 16 pregnant COVID-19 patients had passed away. They also reported that
329 pregnant patients were 1.5 times more likely to be admitted to the ICU (95% CI: 1.2,
330 1.8) and 1.7 times more likely to receive mechanical ventilation (95% CI: 1.2, 2.4).
331 Another national study from Sweden also found that pregnant patients were 5 times
332 more likely to be admitted to the ICU and 4 times more like to receive mechanical
333 ventilation than were nonpregnant patients.²³ In our study collecting data up to the
334 April 12, 2020, only 1 maternal death at 35 days after delivery was recorded, which
335 was lower than that of nonpregnant patients. Pregnant patients in our study were also
336 less likely to be in the more severe condition of illness. Even not much was known
337 about the SARS-CoV-2 in early days of the pandemic, the high priority of prenatal
338 care, the effective performance of the maternal and child health care system, the
339 principle of leaving no one unattended, the practice of early diagnose and
340 hospitalization, and the positive supportive treatment under the guide of a
341 multidisciplinary team may contribute to the favorable prognosis of pregnant
342 COVID-19 patients in this study. However, considering the differences of maternal
343 death across regions, further comparisons of the virus strains between different
344 countries may be instructive.

345

346 The findings of present study also provide more reliable evidence towards the
347 management of pregnant women with COVID-19. For mild patients infected with
348 SARS-CoV-2 during early pregnancy, as being pregnant did not associate with
349 increased risk of severe illness, and the prognosis for most of them was favorable, we
350 had no evidence sufficient to terminate pregnancy in current stage. However, special
351 attention must be paid to patients infected with SARS-CoV-2 in the late pregnancy

352 since the risk of severe illness among them seems higher than that of patients infected
353 in early stage and a exacerbations of COVID-19 were observed in women during the
354 postpartum period.⁶ While for severe or critical cases, it is necessary to take both
355 obstetrical situation and the severity of the condition into consideration, to terminate
356 pregnancy at the best time to prevent the occurrence of serious adverse maternal and
357 fetal outcomes.

358

359 It is also worth noting that the findings of the present study are subject to limitation of
360 missing data. We can hardly rule out the existence of missed case due to the pregnant
361 COVID-19 cases were identified based on the uploaded medical records. However,
362 we undertook a meticulous process in reviewing previous literatures and then believed
363 that the present study had the capability to capture a national picture of the impact of
364 COVID-19 on pregnancy. Additionally, given the variation in the clinical process of
365 diagnosis and treatment and the electronic medical records databases among the
366 designated hospitals, some cases had missing values in the laboratory testing. It may
367 lead to misestimation of some characteristics if those with missing data were
368 systematically different from those with available data. Further, collection and
369 comparison of longitudinal data for pregnant women with and without SARS-CoV-2
370 infection during the outbreak is needed to understand the effects of SARS-CoV-2
371 infection on maternal and neonatal outcomes.

372

373 In summary, compared with nonpregnant COVID-19 patients, being pregnant did not
374 represent a risk for severe condition. Moreover, patients infected with SARS-CoV-2
375 in early pregnancy were at lower risk of severe illness than those infected in late
376 pregnancy.

377

378 **Contributors**

379 QL, LC, HJ and DNZ designed the study, collected the data, interpreted the results,

380 and drafted the manuscript. JM collected the data, interpreted the results, and revised
381 the manuscript. JQ, YYZ, YW, DXM conceived of the study, supervised the study,
382 interpreted the results, and revised the manuscript. QL, LC, HJ and DNZ contributed
383 equally and are considered as co-first authors. JQ, YYZ, YW and DXM contributed
384 equally and are considered as co-corresponding authors. All authors contributed to
385 critical reading of, and commented on, the manuscript, helped to interpret the data,
386 and approved the final manuscript.

387

388 **Declaration of interests**

389 The authors declare no conflicts of interest.

390

391 **Acknowledgments**

392 We thank Yanhong Guo, Xinqiang Gao, Qiang Wang (National Health Commission of
393 the PRC), for their approval and support on provision and coordination of collecting
394 data; We would also thank Ying Shi, Luxia Gan (Big Data Centre of National Health
395 Commission for Human Tissue, Organ Transplantation and Medicine), Qimin Zhan,
396 Luxia Zhang, Mai Wang, Na Cui and Yang Xing (National Institute of Health Data
397 Science at Peking University) for providing help for collecting data. We thank all the
398 hospital staff members for their efforts in collecting the information that was used in
399 this study, and all the patients who consented to donate their data for analysis and the
400 medical staff members who are on the front line of caring for patients; We would also
401 thank the editor and peer reviewers for their hard work for this article.

402

403 **Funding**

404 This study was financially supported by Chinese Academy of Engineering
405 (2020-KYGG-01-06), National Natural Science Foundation of China (72042013),
406 Peking University Health Science Center (BMU2020HKYZX001). The mentioned
407 foundation had no role in the study design, data analysis, drafting the manuscript, or
408 decision to submit this article for publication.

409 **Reference**

- 410 1. World Health Organization. Coronavirus disease (COVID-19) Situation Report –
411 164. Geneva: World Health Organization, 2020.
- 412 2. Tang P, Wang J, Song Y. Characteristics and pregnancy outcomes of patients with
413 severe pneumonia complicating pregnancy: a retrospective study of 12 cases
414 and a literature review. *BMC Pregnancy Childbirth* 2018;18(1):434. doi:
415 10.1186/s12884-018-2070-0 [published Online First: 2018/11/06]
- 416 3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new
417 coronavirus of probable bat origin. *Nature* 2020;579(7798):270-73. doi:
418 10.1038/s41586-020-2012-7 [published Online First: 2020/02/06]
- 419 4. Liu H, Wang LL, Zhao SJ, et al. Why are pregnant women susceptible to
420 COVID-19? An immunological viewpoint. *J Reprod Immunol*
421 2020;139:103122. doi: 10.1016/j.jri.2020.103122 [published Online First:
422 2020/04/04]
- 423 5. Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age
424 with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -
425 United States, January 22-June 7, 2020. *MMWR Morb Mortal Wkly Rep*
426 2020;69(25):769-75. doi: 10.15585/mmwr.mm6925a1 [published Online First:
427 2020/06/26]
- 428 6. Chen L, Li Q, Zheng D, et al. Clinical Characteristics of Pregnant Women with
429 Covid-19 in Wuhan, China. *N Engl J Med* 2020;382(25):e100. doi:
430 10.1056/NEJMc2009226 [published Online First: 2020/04/18]
- 431 7. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report
432 based on 116 cases. *Am J Obstet Gynecol* 2020;223(1):111 e1-11 e14. doi:
433 10.1016/j.ajog.2020.04.014 [published Online First: 2020/04/27]
- 434 8. Pearce N. Analysis of matched case-control studies. *BMJ* 2016;352:i969. doi:
435 10.1136/bmj.i969 [published Online First: 2016/02/27]
- 436 9. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With
437 Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional,
438 Multicenter Study. *Am J Gastroenterol* 2020;115(5):766-73. doi:
439 10.14309/ajg.0000000000000620 [published Online First: 2020/04/15]
- 440 10. Tan EK, Tan EL. Alterations in physiology and anatomy during pregnancy. *Best*
441 *Pract Res Clin Obstet Gynaecol* 2013;27(6):791-802. doi:
442 10.1016/j.bpobgyn.2013.08.001 [published Online First: 2013/09/10]
- 443 11. Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic
444 characteristics of monocytes and granulocytes in normal pregnancy and
445 maternal infection. *Am J Obstet Gynecol* 2001;185(5):1118-23. doi:
446 10.1067/mob.2001.117682 [published Online First: 2001/11/22]
- 447 12. Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and
448 challenges. *The Lancet Gastroenterology & Hepatology* 2020;5(5):428-30. doi:
449 10.1016/s2468-1253(20)30057-1
- 450 13. Forestieri S, Marcialis MA, Migliore L, et al. Relationship between pregnancy and

- 451 coronavirus: what we know. *J Matern Fetal Neonatal Med* 2020:1-12. doi:
452 10.1080/14767058.2020.1771692 [published Online First: 2020/06/06]
- 453 14. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. COVID-19 infection among
454 asymptomatic and symptomatic pregnant women: Two weeks of confirmed
455 presentations to an affiliated pair of New York City hospitals. *Am J Obstet*
456 *Gynecol MFM* 2020:100118. doi: 10.1016/j.ajogmf.2020.100118 [published
457 Online First: 2020/04/16]
- 458 15. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and
459 chemokines in severe acute respiratory syndrome. *Clin Exp Immunol*
460 2004;136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x [published
461 Online First: 2004/03/20]
- 462 16. Aghaeepour N, Ganio EA, McIlwain D, et al. An immune clock of human
463 pregnancy. *Science Immunology* 2017;2(15) doi: 10.1126/sciimmunol.aan2946
- 464 17. Sarapultsev A, Sarapultsev P. Immunological environment shifts during pregnancy
465 may affect the risk of developing severe complications in COVID-19 patients.
466 *Am J Reprod Immunol* 2020:e13285. doi: 10.1111/aji.13285 [published Online
467 First: 2020/06/10]
- 468 18. Little P, Read RC, Amlot R, et al. Reducing risks from coronavirus transmission in
469 the home-the role of viral load. *BMJ* 2020;369:m1728. doi:
470 10.1136/bmj.m1728 [published Online First: 2020/05/08]
- 471 19. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients
472 infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:
473 retrospective cohort study. *BMJ* 2020;369:m1443. doi: 10.1136/bmj.m1443
474 [published Online First: 2020/04/23]
- 475 20. Westgren M, Pettersson K, Hagberg H, et al. Severe maternal morbidity and
476 mortality associated with COVID-19: The risk should not be downplayed.
477 *Acta Obstet Gynecol Scand* 2020;99(7):815-16. doi: 10.1111/aogs.13900
478 [published Online First: 2020/05/10]
- 479 21. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal Death Due to
480 COVID-19 Disease. *Am J Obstet Gynecol* 2020 doi:
481 10.1016/j.ajog.2020.04.030 [published Online First: 2020/05/04]
- 482 22. Amorim M, Soligo TM, Fonseca E. Maternal deaths with coronavirus disease
483 2019: a different outcome from low- to middle-resource countries? *Am J*
484 *Obstet Gynecol* 2020 doi: 10.1016/j.ajog.2020.04.023
- 485 23. Collin J, Byström E, Carnahan A, et al. Pregnant and postpartum women with
486 SARS-CoV-2 infection in intensive care in Sweden. *Acta Obstet Gynecol*
487 *Scand* 2020 doi: 10.1111/aogs.13901 %/ This article is protected by copyright.
488 All rights reserved.

489

490 **Tables:**

491 **Table 1. Baseline characteristics of pregnant Covid-19 patients and matched**

492 **comparators. ***

Characteristic	Pregnant patients (n=138)	Non-pregnant patients (n=138)	<i>p-value</i>
Mean of age (SD)-years	30.4 (4.3)	30.4 (4.3)	0.857
Region-no. (%)			
Hubei province	102 (73.9)	102 (73.9)	1.000
Other provinces	36 (26.1)	36 (26.1)	
Pregnancy period when infected-no. (%)			
First trimester	28 (20.3)	-	-
Second trimester	31 (22.5)	-	
Third trimester	79 (57.2)	-	
Disease Severity-no. (%)			
Mild case	121 (87.7)	115 (83.3)	0.306
Severe case	17 (12.3)	23 (16.7)	
Complications-no. (%)			
No	130 (94.2)	121 (87.7)	0.048
Yes	8 (5.8)	17 (12.3)	
Outcomes-no. (%)			
Cured	137 (99.3)	135 (97.8)	0.341
Death	1 (0.7)	3 (2.2)	
Mean of hospital stay (SD)-days	15.9 (8.8)	15.9 (9.9)	0.999

493 * Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus
 494 disease 2019, and SD denotes standard deviation.

495

Table 2. Clinical features of Covid-19 patients in pregnant. *

Characteristic	Trimester 1 (n=28)	Trimester 2 (n=31)	Trimester 3 (n=79)	p-value
Demography				
Mean of age (SD)-years	30.7 (5.0)	30.8 (4.6)	30.2 (3.9)	0.692
Living in Hubei Province	19 (68)	20 (65)	63 (80)	0.171
Condition-no. (%)				
Severe case	0 (0)	4 (13)	13 (16)	0.053
Death	0 (0)	0 (0)	1 (1)	1.000
Presenting signs and symptoms--no./total no. (%)				
Asymptomatic	1/28 (4)	1/31 (3)	9/79 (11)	0.345
Fever	18/27 (67)	21/31 (68)	56/79 (71)	0.904
Cough	17/28 (64)	28/31 (90)	50/79 (63)	0.011 [†]
Chest tightness	4/27 (15)	9/31 (29)	21/79 (27)	0.384
Dyspnea	2/27 (7)	2/31 (7)	12/79 (15)	0.439
Fatigue	5/27 (19)	7/31 (23)	10/79 (13)	0.367
Diarrhea	3/27 (11)	1/31 (3)	6/79 (8)	0.535
Myalgia	6/27 (22)	2/31 (7)	4/79 (5)	0.032 [†]
Headache	3/27 (11)	3/31 (10)	5/79 (6)	0.628
Nasal congestion	1/27 (4)	4/31 (13)	5/79 (6)	0.389
Sore throat	2/27 (7)	1/30 (3)	6/79 (8)	0.800
Nausea or vomiting	2/27 (7)	2/31 (7)	1/79 (1)	0.126
Chest pain	1/27 (4)	2/31 (7)	2/77 (3)	0.589
Laboratory findings-no./total no. (%)				
Leucocytes ($\times 10^9$ per mm^3)				
Median (IQR)	5.9 (5.1-7.5)	6.9 (4.8-9.3)	6.6 (5.1-8.8)	0.254

<3.5×10 ⁹ per mm ³	4/28 (14)	1/31 (3)	2/76 (3)	0.078
>9.5×10 ⁹ per mm ³	2/28 (7)	8/31 (26)	16/76 (21)	
Lymphocytes (×10 ⁹ per mm ³)				
Median (IQR)	1.4 (1.1-1.7)	1.1 (0.8-1.5)	1.0 (0.8-1.5)	0.060
<1.1×10 ⁹ per mm ³	8/28 (29)	16/30 (53)	43/74 (58)	0.026 [†]
Hemoglobin (g/liter)				
Median (IQR)	124 (112-131)	111 (104-115)	114 (104-124)	<0.001
Hemoglobin <110 g/liter	3/25 (11)	14/30 (47)	29/74 (39)	0.005 [†]
Platelets (×10 ⁹ per mm ³)				
Median (IQR)	211 (174-251)	208 (175-252)	182 (151-251)	0.192
<100×10 ⁹ per mm ³	0/28 (0)	0/30 (0)	3/73 (4)	0.583
Albumin (g/liter)				
Median (IQR)	41.8 (38.1-45.3)	34.4 (31.6-36.4)	33.2 (31.3-34.7)	<0.001
<35 g/liter	3/26 (12)	13/25 (52)	43/56 (77)	<0.001
Fibrinogen (g/liter)				
Median (IQR)	3.0 (2.8-4.1)	4.0 (3.4-5.1)	4.2 (3.8-4.8)	0.098
>4 g/liter	7/25 (28)	13/25 (52)	37/58 (64)	0.011 [†]
D-dimer (mg/liter)				
Median (IQR)	0.4 (0.2-1.1)	0.9 (0.6-1.3)	1.3 (0.9-2.2)	0.014 [†]
≥0.5mg/liter	12/26 (46)	18/23 (78)	61/64 (95)	<0.001
Alanine aminotransferase (U/liter)				
Median (IQR)	17 (10-32)	17 (11-24)	18 (12-48)	0.245
>40U/liter	4/26 (15)	3/23 (13)	17/61 (28)	0.271
>120U/liter	0/26 (0)	1/23 (4)	4/61 (7)	0.503
Aspartate aminotransferase (U/liter)				
Median (IQR)	18 (15-24)	23 (16-28)	26 (19-43)	0.113
>40U/liter	3/26 (12)	2/23 (9)	17/60 (28)	0.071

>120U/liter	0/26 (0)	0/23 (0)	6/60 (10)	0.109
Lactate dehydrogenase (U/liter)				
Median (IQR)	161 (146-192)	179 (159-230)	207 (180-296)	0.060
>245U/liter	3/24 (13)	5/22 (23)	19/47 (40)	0.042 [†]
Creatine Kinase (U/liter)				
Median (IQR)	45 (31-49)	29 (23-39)	43 (27-105)	0.021 [†]
≥200 U/liter	0/25 (0)	0/21 (0)	4/41 (10)	0.186
C-reactive protein >10mg/lite	7/26 (27)	20/30 (67)	52/69 (75)	<0.001 [†]
Procalcitonin ≥0.1ng/ml	0/20 (0.0)	2/19 (11)	15/47 (32)	0.003
Radiographic findings-no./total no. (%)				
Bilateral involvement	14/23 (61)	17/20 (85)	59/75 (79)	0.144
Unilateral involvement	6/23 (26)	3/20 (15)	14/75 (19)	0.667
No abnormality	3/23 (13)	0/20 (0)	2/75 (3)	0.104
Treatment-no./total no. (%)				
Antibiotic therapy	16/28 (57)	17/31 (55)	63/79 (80)	0.010 [†]
Antiviral therapy	21/28 (75)	24/31 (77)	57/79 (72)	0.898
Glucocorticoids	0/28 (0)	10/31 (32)	23/79 (32)	<0.001 [†]
Immune globulin	2/28 (7)	7/31 (23)	16/79 (20)	0.228
Traditional Chinese medicine	15/28 (54)	15/31 (48)	28/79 (35)	0.169
Oxygen support [‡]	5/28 (18)	16/31 (52)	48/79 (61)	<0.001 [†]
Mechanical ventilation	0/28(0)	0/31 (0)	3/79 (4)	0.576

* Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus disease 2019, SD denotes standard deviation, and IQR denotes interquartile range.

[†] p<0.05.

[‡] Oxygen support including nasal cannula, high flow oxygen and Invasive mechanical ventilation.

Table 3. Clinical features of Covid-19 patients in pregnant and matched comparator.*

Characteristic	Pregnant patients (n=138)	Non-pregnant patients (n=138)	Odds Ratio (95% CI) or P value for difference
Manifestations-no./total no. (%)			
Asymptomatic	11/138 (8.0)	6/138 (4.3)	1.83 (0.68 to 4.96)
Fever	95/137 (69.3)	100/138 (72.5)	0.87 (0.52 to 1.46)
Cough	96/138 (69.6)	101/137 (73.2)	0.83 (0.49 to 1.42)
Chest tightness	34/137 (24.8)	50/138 (36.2)	0.61 (0.36 to 1.02)
Dyspnea	16/137 (11.7)	22/138 (15.9)	0.71 (0.37 to 1.39)
Fatigue	22/137 (16.1)	42/138 (30.4)	0.44 (0.25 to 0.80) [†]
Diarrhea	10/137 (7.3)	21/138 (15.2)	0.38 (0.15 to 0.96) [†]
Myalgia	12/137 (8.8)	22/138 (15.9)	0.50 (0.23 to 1.07)
Headache	11/137 (8.0)	21/138 (15.2)	0.50 (0.22 to 1.11)
Nasal congestion	10/137 (7.3)	14/138 (10.1)	0.60 (0.22 to 1.65)
Sore throat	9/137 (6.6)	15/138 (10.9)	0.57 (0.24 to 1.36)
Nausea or vomiting	5/137 (3.6)	14/138 (10.1)	0.25 (0.07 to 0.89) [†]
Chest pain	5/137 (3.6)	10/138 (7.2)	0.50 (0.17 to 1.46)
Laboratory findings-no./total no. (%)			
Leucocytes ($\times 10^9$ per mm^3)			
Median (IQR)	6.5 (5.0-8.5)	4.7 (3.8-6.1)	$p < 0.001$
$< 3.5 \times 10^9$ per mm^3	7/135 (5.2)	24/130 (18.5)	0.26 (0.11 to 0.64) [†]
$> 9.5 \times 10^9$ per mm^3	26/135 (19.3)	3/130 (2.3)	12.50 (2.96 to 52.77) [†]
Lymphocytes ($\times 10^9$ per mm^3)			
Median (IQR)	1.1 (0.8-1.5)	1.4 (1.0-1.9)	$p < 0.001$
$< 1.1 \times 10^9$ per mm^3	67/132 (50.8)	40/130 (30.8)	2.04 (1.24 to 3.36) [†]

Hemoglobin (g/liter)			
Median (IQR)	113 (107-124)	124 (116-132)	$p<0.001$
<110 g/liter	46/132 (34.8)	18/131 (13.7)	3.64 (1.87 to 7.09) [†]
Platelets ($\times 10^9$ per mm^3)			
Median (IQR)	195 (155-244)	204 (162-252)	$p=0.891$
<100 $\times 10^9$ per mm^3	3/131 (2.3)	7/131 (5.3)	0.33 (0.07 to 1.65)
Albumin (g/liter)			
Median (IQR)	34.1 (31.6-38.2)	41.7 (39.2-44.2)	$p<0.001$
<35 g/liter	59/107 (55.1)	7/112 (6.2)	12.75 (4.61 to 35.28) [†]
Fibrinogen (g/liter)			
Median (IQR)	4.1 (3.3-4.7)	3.1 (2.5-3.6)	$p<0.001$
>4 g/liter	57/108 (52.8)	18/116 (15.5)	44.00 (6.06 to 319.37) [†]
D-dimer (mg/liter)			
Median (IQR)	1.1 (0.6-1.8)	0.2 (0.2-0.4)	$p=0.003$
≥ 0.5 mg/liter	91/113 (80.5)	23/118 (19.5)	11.00 (4.77 to 25.37) [†]
Alanine aminotransferase (U/liter)			
Median (IQR)	18 (12-35)	15 (11-23)	$p=0.003$
> 40U/liter	24/110 (21.8)	7/110 (6.4)	3.17 (1.26 to 7.93) [†]
>120U/liter	5/110 (4.5)	0/110 (0.0)	Not available
Aspartate aminotransferase (U/liter)			
Median (IQR)	23 (17-34)	18 (15-23)	$p=0.005$
> 40U/liter	22/109 (20.2)	3/110 (2.7)	6.00 (1.77 to 20.37) [†]
>120U/liter	6/109 (5.5)	0/110 (0.0)	Not available
Lactate dehydrogenase (U/liter)			
Median (IQR)	195 (162-264)	172 (143-206)	$p=0.089$
>245U/liter	27/93 (29.0)	14/99 (14.1)	2.37 (1.04 to 5.43) [†]
Creatine Kinase (U/liter)			

Median (IQR)	39 (26-64)	56 (42-70)	$p=0.320$
≥200 U/liter	4/87 (4.6)	4/88 (4.5)	0.50 (0.09 to 2.73)
C-reactive protein >10mg/liter	79/125 (63.2)	40/108 (37.0)	2.77 (1.47 to 5.22) [†]
Procalcitonin ≥0.1ng/ml	17/86 (19.8)	10/94 (10.6)	1.33 (0.56 to 3.16)
<i>Radiographic findings-no./total no. (%)</i>			
Chest CT scan			
Bilateral involvement	90/118 (76.3)	80/131 (61.1)	2.38 (1.25 to 4.56) [†]
Unilateral involvement	23/118 (19.5)	38/131 (29.0)	0.48 (0.24 to 0.96)
No abnormality	5/118 (4.2)	13/131 (9.9)	0.50 (0.17 to 1.46)
<i>Treatment-no. (%)</i>			
Antibiotic therapy	96 (69.6)	92 (66.7)	1.15 (0.68 to 1.95)
Antiviral therapy	102 (73.9)	132 (95.7)	0.09 (0.03 to 0.30) [†]
Glucocorticoids	35 (25.4)	28 (20.3)	1.33 (0.76 to 2.35)
Immune globulin	25 (18.1)	14 (10.1)	2.10 (0.99 to 4.46)
Traditional Chinese medicine	58 (42.0)	90 (65.2)	0.36 (0.21 to 0.62) [†]
Oxygen support [‡]	69 (50.0)	59 (42.8)	1.40 (0.84 to 2.34)
Mechanical ventilation	3 (2.2)	3 (2.2)	1.00 (0.20 to 4.95)

* Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus disease 2019, and IQR denotes interquartile range.

† $p<0.05$.

‡ Oxygen support including nasal cannula, high flow oxygen and Invasive mechanical ventilation.

Figures

Figure 1. Distribution of pregnant patients with Covid-19 across mainland China

Legend:

Shown are the uploaded, confirmed pregnant cases of coronavirus disease 2019 (Covid-19) throughout China, according to the National Health Commission as of April 30, 2020.

